Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The effect of greater occipital nerve blockade on the quality of life, disability and comorbid depression, anxiety, and sleep disturbance in patients with chronic migraine

  • 20 Accesses

Abstract

Objective

The greater occipital nerve block (GONB) with local anesthetics is an effective treatment for chronic migraine (CM). In this study, it was aimed to demonstrate the change in quality of life, depression, anxiety, and sleep disturbance scores before and after treatment in CM patients who underwent GONB and the effectiveness of treatment.

Patients and methods

The study included 84 patients diagnosed as CM according to the International Classification of Headache Disorders III beta version diagnostic criteria. The 24-Hour Migraine Quality of Life Questionnaire (MQoLQ), Migraine Disability Assessment Scale (MIDAS), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), Headache Impact Test (HIT), and Visual Analog Scale (VAS) were applied on patients before GONB treatment and at posttreatment months 1 and 3.

Results

MQoLQ scores, which measured the daily quality of life, were 38 [3–66] before GONB treatment, and 64 [38–88] in the first month and 72 [40–86] in the third month after treatment. In addition, this increase was statistically significant (p < 0.001). Furthermore, we found a statistically significant decrease in disability, depression, anxiety, and sleep disturbance scores after treatment (p < 0.05).

Conclusion

In this study, we observed a prominent improvement in quality of life and disability rates of CM patients treated with GONB compared to pretreatment. We also demonstrated that the treatment was effective in comorbid depression, anxiety, and sleep disturbance scores.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Lipton RB, Stewart RS, Diamond S et al (2001) Prevalence and burden of migraine in the USA: data from the Amerikan Migraine Study 2. Headache 41:646–657

  2. 2.

    Blumenfeld AM, Varon SF, Buse DC et al (2010) Disability, HRQOL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS). Cephalalgia 31:301–315

  3. 3.

    Natoli JL, Manack A, Dean B et al (2010) Global prevalence of chronic migraine: a systematic review. CephalalgiaInt J Headache 30:599–609

  4. 4.

    Zhang H, Zhang H, Wei Y, Lian Y, Chen Y, Zheng Y (2017) Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin a: a prospective pilot study. Int J Neurosci 127:285–290

  5. 5.

    Diener H-C, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD (2012) Chronic migraine-classification, characteristics and treatment. Nat Rev Neurol 14:162–171

  6. 6.

    Gul HL, Ozon AO, Karadas O, Koc G, Inan LE (2017) The efficacy of greater occipital nerve blockade in chronic migraine: a placebo-controlled study. Acta Neurol Scand 136:138–144

  7. 7.

    Cuadrado ML, Aledo-Serrano Á, Navarro P, López-Ruiz P, Fernández-de-Las-Peñas C, González-Suárez I, Orviz A, Fernández-Pérez C (2017) Short-term effects of greater occipital nerve blocks in chronic migraine: a double- blind, randomised, placebo- controlled clinical trial. Cephalalgia 37:864–872

  8. 8.

    Giannini G, Cevoli S, Sambati L, Cortelli P (2012) Migraine: risk factor and comorbidity. Neurol Sci 33:37–41

  9. 9.

    Negro A, D'Alonzo L, Martelletti P (2010) Chronic migraine: comorbidities, risk factors, and rehabilitation. Intern Emerg Med 5:13–19

  10. 10.

    Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P (2018) Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache 58:700–714

  11. 11.

    Hartmaier SL, Santanello NC, Epstein RS, Silberstein SD (1995) Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache 35:320–329

  12. 12.

    Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963–974

  13. 13.

    Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56:20–28

  14. 14.

    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571

  15. 15.

    Ulusoy MSN, Erkmen H (1998) Turkish version of the beck anxiety inventory: psychometric properties. CognPsychother 12:163–172

  16. 16.

    Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213

  17. 17.

    Ünal-Artık HA, İnan LE, Ataç-Uçar C, Yoldas TK (2017) Do bilateral and unilateral greater occipital nerve block effectiveness differ in chronic migraine patients? Neurol Sci 38:949–954

  18. 18.

    Palamar D, Uluduz D, Saip S, Erden G, Unalan H, Akarirmak U (2015) Ultrasound-guided greater occipital nerve block: an efficient technique in chronic refractory migraine without aura? Pain Physician 18:153–162

  19. 19.

    AynurÖzge DU, ÖzgürYalın O et al (2018) Chronic migraine: burden, comorbidities, and treatment. Turk J Neurol 24:117–125

  20. 20.

    Vanderpol J, Jonker L (2019) Influence of patient positioning on reported clinical outcomes after greater occipital nerve block for treatment of headache: results from prospective single-centre, non-randomised, proof-of-concept study. Clin Neurol Neurosurg. 176:73–77

  21. 21.

    Caproni S, Bianchi E, Cupin LM et al (2015) Migraine-specific quality of life questionnaire and relapse of medication overuse headache. BMC Neurol 15:85–90

  22. 22.

    Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB (2010) Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med 52:8–14

  23. 23.

    Chen YC, Tang CH, Ng K, Wang SJ (2012) Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan. J Headache Pain 13:311–319

  24. 24.

    Demiryurek BE, Ertem DH, Tekin A et al (2016) Effects of onabotulinumtoxin. A treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurol Sci 37:1779–1784

  25. 25.

    İnan N, İnan LE, Coşkun Ö, TuğbaTunç Mİ (2016) Effectiveness of greater occipital nerve blocks in migraine prophylaxis. Arch Neuropsychiatr 53:45–48

  26. 26.

    Vigano A, Torrieri MC, Toscano M et al (2018) Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. J Headache Pain 19:73–82

  27. 27.

    Gopaldas M, Zanderigo F, Zhan S et al (2019) Brain serotonin transporter binding, plasma arachidonic acid and depression severity: a positron emission tomography study of major depression. J Affect Disord 257:495–503

  28. 28.

    Kelman L, Rains JC (2005) Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache 45:904–910

  29. 29.

    Cupini LM, DeMurtas M, Costa C, Mancini M, Eusebi P, Sarchielli P, Caldoresi P (2009) Obsessive-compulsive disorder and migraine with medication overuse headache. Headache 49:1005–1013

  30. 30.

    Guitera V, Munoz P, Castillo J, Pascual J (2002) Quality of life in chronic daily headache: a study in a general population. Neurology 58:1062–1065

Download references

Author information

Correspondence to Ersin Kasım Ulusoy.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Declaration of interest

The authors alone are responsible for the content and writing of the paper.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ulusoy, E.K., Bolattürk, Ö.F. The effect of greater occipital nerve blockade on the quality of life, disability and comorbid depression, anxiety, and sleep disturbance in patients with chronic migraine. Neurol Sci (2020). https://doi.org/10.1007/s10072-020-04286-9

Download citation

Keywords

  • Chronic Migraine
  • Quality of life
  • Disability
  • Depression
  • Anxiety